Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.

Inclusion Criteria: * Age over 18 years * Newly diagnosed cases with diagnostic criteria for EoE (ie at least 15 eosinophils per high power field (Magnification 10 times 40 = x400) in any field of view in any esophageal biopsy and concurrent symptoms of esophageal dysfunction mainly dysphagia. * Women of childbearing age may participate provided that the pregnancy is not planned , and that contraceptive use during therapy. The investigator will arrange a free pregnancy test must be performed within 1 week before treatment and be negative. * Participation requires oral and written informed and signed consent form (see patient information and consent forms). Exclusion Criteria: * Local infection of the pharynx or esophagus , such as fungal, bacterial or viral infection * Active or latent tuberculosis in respiratory tract * Recent history of major trauma or major surgery * Recent significant infection or other physical stress * Signs or suspicion of dehydration * History of injury, illness or surgery in the adrenals or pituitary * Pharynx or esophagussurgery or other trauma in the esophagus (incl. foreign body with a sharp object ) where healing has not taken place. (in case of doubt to be assessed by esophago - gastroscopy. * Planned elective surgery during treatment * Pregnancy, ongoing or planned * Women of childbearing potential not using preventives during the study period * Glaucoma * Hypersensitivity to any component in the treatments * Systemic or local steroid treatment last 4 months * Contraindication to steroid therapy ( immune deficiency or suppression , stomach ulcers, diabetes) * Medications that affect oesophageal motility (cisapride, erythromycin ) during the treatment period . * PPIs during or up to 2 weeks before the treatment period * Other cause of dysphagia (cancer, connective tissue disease , neurological disease ) * Volunteer who can not consent to the study or complete a questionnaire